| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.87 [0.69, 1.10] | | < 1 | | 72% | 3 studies (3/-) | 87.4 % | low | not evaluable | high | crucial | - |
| deaths (OS) (extension) | 0.73 [0.64, 0.83] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| MFS | 1.01 [0.57, 1.80] | | < 1 | | 92% | 2 studies (2/-) | 48.5 % | low | not evaluable | high | important | - |
| MFS (extension) | 0.76 [0.64, 0.90] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | important | - |
| progression or deaths (PFS) | 0.89 [0.66, 1.21] | | < 1 | | 0% | 1 study (1/-) | 77.3 % | NA | not evaluable | | important | - |
| RFS (extension) | 1.03 [0.55, 1.90] | | < 1 | | 96% | 2 studies (2/-) | 46.7 % | low | not evaluable | high | important | - |
| RFS/DFS | 1.07 [0.53, 2.16] | | < 1 | | 96% | 2 studies (2/-) | 42.7 % | low | not evaluable | high | important | - |
| DCR | 1.19 [0.86, 1.63] | | > 1 | | 0% | 1 study (1/-) | 85.6 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 1.31 [0.86, 2.00] | | > 1 | | 0% | 1 study (1/-) | 89.3 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| AE (any grade) | 3.95 [1.10, 14.25] | | < 1 | | 76% | 2 studies (2/-) | 1.8 % | low | not evaluable | high | non important | - |
| AE (grade 3-4) | 0.64 [0.02, 18.93] | | < 1 | | 100% | 2 studies (2/-) | 59.9 % | low | not evaluable | high | non important | - |
| TRAE (any grade) | 5.16 [1.59, 16.78] | | < 1 | | 96% | 3 studies (3/-) | 0.3 % | low | not evaluable | high | non important | - |
| TRAE (grade 3-4) | 6.84 [2.37, 19.72] | | < 1 | | 95% | 3 studies (3/-) | 0.0 % | low | not evaluable | high | non important | - |
| TRAE leading to death (grade 5) | 3.19 [0.84, 12.04] | | < 1 | | 0% | 3 studies (3/-) | 4.4 % | low | not evaluable | high | non important | - |
| TRAE leading to discontinuation (any grade) | 7.06 [1.79, 27.86] | | < 1 | | 97% | 3 studies (3/-) | 0.3 % | low | not evaluable | high | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 5.10 [1.02, 25.41] | | < 1 | | 96% | 2 studies (2/-) | 2.4 % | low | not evaluable | high | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Adrenal insufficiency TRAE (grade 3-4) | 2.00 [0.44, 9.17] | | < 1 | | 0% | 2 studies (2/-) | 18.6 % | low | not evaluable | high | non important | - |
| Colitis TRAE (grade 3-4) | 7.92 [0.47, 133.48] | | < 1 | | 86% | 2 studies (2/-) | 7.8 % | low | not evaluable | high | non important | - |
| Diarrhoea TRAE (grade 3-4) | 5.99 [1.52, 23.56] | | < 1 | | 87% | 3 studies (3/-) | 0.5 % | low | not evaluable | high | non important | - |
| Endocrine disorders TRAE (grade 3-4) | 8.58 [0.50, 148.05] | | < 1 | | 86% | 2 studies (2/-) | 7.2 % | low | not evaluable | high | non important | - |
| Eye disorders TRAE (grade 3-4) | 0.50 [0.02, 14.85] | | < 1 | | 0% | 1 study (1/-) | 65.5 % | NA | not evaluable | | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 3.99 [0.18, 88.89] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Gastrointestinal disorders TRAE (grade 3-4) | 7.08 [1.54, 32.51] | | < 1 | | 93% | 3 studies (3/-) | 0.6 % | low | not evaluable | high | non important | - |
| Guillain-Barré syndrome TRAE (grade 3-4) | 3.99 [0.18, 88.89] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 2.51 [0.48, 13.01] | | < 1 | | 0% | 1 study (1/-) | 13.8 % | NA | not evaluable | | non important | - |
| Hepatobiliary disorders TRAE (grade 3-4) | 16.04 [2.04, 126.16] | | < 1 | | 74% | 2 studies (2/-) | 0.4 % | low | not evaluable | high | non important | - |
| Hypersensitivity TRAE (grade 3-4) | 1.98 [0.17, 22.37] | | < 1 | | 14% | 2 studies (2/-) | 29.2 % | low | not evaluable | high | non important | - |
| Hypophysitis TRAE (grade 3-4) | 4.76 [0.91, 24.98] | | < 1 | | 68% | 3 studies (3/-) | 3.3 % | low | not evaluable | high | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 2.00 [0.28, 14.21] | | < 1 | | 0% | 2 studies (2/-) | 24.6 % | low | not evaluable | high | non important | - |
| Increase AST TRAE (grade 3-4) | 9.24 [2.79, 30.59] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | low | not evaluable | high | non important | - |
| Increased ALT TRAE (grade 3-4) | 5.64 [2.50, 12.71] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | low | not evaluable | high | non important | - |
| Increased lipase level TRAE (grade 3-4) | 1.99 [0.07, 59.56] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 3.99 [0.18, 88.89] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 7.32 [0.82, 65.03] | | < 1 | | 0% | 2 studies (2/-) | 3.8 % | low | not evaluable | high | non important | - |
| Nervous system disorders TRAE (grade 3-4) | 12.34 [1.59, 95.62] | | < 1 | | 0% | 2 studies (2/-) | 0.8 % | low | not evaluable | high | non important | - |
| Pancreatitis TRAE (grade 3-4) | 1.99 [0.07, 59.56] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Pancytopenia TRAE (grade 3-4) | 1.99 [0.07, 59.56] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Pericarditis TRAE (grade 3-4) | 1.99 [0.07, 59.56] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 3.99 [0.18, 88.89] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 8.03 [0.42, 152.51] | | < 1 | | 0% | 1 study (1/-) | 8.5 % | NA | not evaluable | | non important | - |
| Polymyalgia Rheumatica TRAE (grade 3-4) | 0.50 [0.02, 14.85] | | < 1 | | 0% | 1 study (1/-) | 65.5 % | NA | not evaluable | | non important | - |
| Pruritic rash TRAE (grade 3-4) | 0.50 [0.02, 14.85] | | < 1 | | 0% | 1 study (1/-) | 65.5 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 2.44 [0.27, 22.33] | | < 1 | | 40% | 2 studies (2/-) | 21.6 % | low | not evaluable | high | non important | - |
| Rash TRAE (grade 3-4) | 3.06 [1.33, 7.07] | | < 1 | | 0% | 3 studies (3/-) | 0.4 % | low | not evaluable | high | non important | - |
| Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) | 8.04 [1.00, 64.42] | | < 1 | | 0% | 2 studies (2/-) | 2.5 % | low | not evaluable | high | non important | - |
| Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 4.67 [1.08, 20.14] | | < 1 | | 68% | 3 studies (3/-) | 2.0 % | low | not evaluable | high | non important | - |
| Thyroiditis TRAE (grade 3-4) | 1.99 [0.07, 59.56] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Uveitis TRAE (grade 3-4) | 0.50 [0.02, 14.85] | | < 1 | | 0% | 1 study (1/-) | 65.5 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
| Abdominal pain AE (grade 3-4) | 0.04 [0.01, 0.17] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Colitis AE (grade 3-4) | 6.26 [2.61, 15.03] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| Cough AE (grade 3-4) | 0.01 [0.00, 0.15] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
| Decreased appetite AE (grade 3-4) | 0.06 [0.01, 0.46] | | < 1 | | 0% | 1 study (1/-) | 99.6 % | NA | not evaluable | | non important | - |
| Diarrhoea AE (grade 3-4) | 0.26 [0.18, 0.37] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 0.05 [0.03, 0.10] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Headache AE (grade 3-4) | 0.04 [0.01, 0.11] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Hypophysitis AE (grade 3-4) | 11.01 [2.57, 47.24] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
| Hypothyroidism AE (grade 3-4) | 0.14 [0.02, 1.16] | | < 1 | | 0% | 1 study (1/-) | 96.5 % | NA | not evaluable | | non important | - |
| Increase AST AE (grade 3-4) | 0.80 [0.45, 1.45] | | < 1 | | 0% | 1 study (1/-) | 76.6 % | NA | not evaluable | | non important | - |
| Increased ALT AE (grade 3-4) | 0.97 [0.55, 1.70] | | < 1 | | 0% | 1 study (1/-) | 54.8 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 0.01 [0.00, 0.07] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Pruritus AE (grade 3-4) | 0.14 [0.07, 0.26] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Pyrexia AE (grade 3-4) | 0.21 [0.08, 0.56] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
| Rash AE (grade 3-4) | 0.06 [0.03, 0.15] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 0.07 [0.02, 0.29] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Weight decreased AE (grade 3-4) | 0.02 [0.00, 0.16] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
